{"name":"Tauber Eye Center","slug":"tauber-eye-center","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Lifitegrast Ophthalmic","genericName":"Lifitegrast Ophthalmic","slug":"lifitegrast-ophthalmic","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Lifitegrast Ophthalmic","genericName":"Lifitegrast Ophthalmic","slug":"lifitegrast-ophthalmic","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQXzNxZ0NvdGxhLTljQ2hGYmFtWDQtUjA0Nm1PdG1mSnVuenhQWlRia05TQUFNQXNhaDJOOFpyVkJBVzFuTHFpZnV0YnJpZXRyU3U4TGJlZ0RvNmpYdXNGNk5pdDJmVl9UU3lRandkeVJkcWpKczJyRmYtb3liYUptMlNfcUZaZGs?oc=5","date":"2022-03-26","type":"pipeline","source":"Ophthalmology Times","summary":"Vial launches ophthalmology site network - Ophthalmology Times","headline":"Vial launches ophthalmology site network","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxPR3FjTEF0T3FfRE9RVm8xUUxHM1Y0aE9GUmxoZVMydkg2TWV5UU9fbGNmeVBWUlY1OFcyeUhkY1UtMDNCaDRzSDNMUHlqUHJQRDJaMGZGWWo0OWhidFdqNWVVLTBRXzY3N0FNV1Z3RkotUXppSFNmaWR0a3RqNG5peFFqdk42Sy0wcEt6OVVBbUd1NXhXSDNuLTBQZEF0d0tWZmlBTGNNVFVXQjhwckp6TFR2X0tkX29SNVUtRlpUMkZCOTY4ZHI5QVVDRU1LbzZRY0wyM05xREJwUmx3SzlxRW9VX0NhYVk1YjliQTN4akwxNG0tdFd2V2JpQXROTWZCNDctcXZha011eTlaWnlQMkNRSzg?oc=5","date":"2022-03-22","type":"trial","source":"PR Newswire","summary":"VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease - PR Newswire","headline":"VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry E","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2gJBVV95cUxNdVRFNmZraWJnV2tZWjc4ZEdBNGNGOXNtODJDRlQ3Qm9vWS16bDhKQXE0MkVSeTNRdzRfcHp6SGNGSVUwODhYUGpwZHNJbnd0T0lMMDRhNzRDVXFGRlNXNzdOS2FIWGVMMjQwTF9fVFh3c2NLSC1PSlRyY0NhTTcwTV9CSlNDd0ZZSGNxcE1fR0ZtUjFZemNZdU5EeWNfel9EeUxfTXpGdmtYS1ZQNHltQXoxU1ZrOTNKMWFMM3JHbEhjaWoxRDJjVFVWQXlMNWpZclpfRV9yZG02aGRMcEhvN21tTGs1bHYzZGFtdUk4TnFfcG1hdDFuSHZ3R2hGeTZaZTB2cmtmVnVhZzZBSTdyQnRXUVNFX2pDZ2JXRFZCMVl5blRCT3RHUklfM3hFN2V1RFYwVENjOGViRWVJTkYybGV3SEladXlLZHU3eUFyVjBIZWFwYjJwWDZB?oc=5","date":"2021-04-13","type":"trial","source":"Newswire Canada","summary":"Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction - Newswire","headline":"Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexylo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPVnBkRVRrRkl1cUNDV0FvZ0YzV1hZYTBIUmZHeVZrcHNMUmt0ajFsMnBmbkswZUxNSmJzNGo0TnlDQktKWU02RHc2ZlJnWEtmVGhHTzJVTjdJSWNEbmVSa2prLS1sTGNNRU43SVJQRmZlVlMwQlpwS2otVjJZZXlnLVpQbG9zVHBrT2syeG5OTzFvSG9vLTVUN2F0QkF0YVdOQTRkUGdDTmptSVR2ZTJVVUVCNGJRSkZ6bjdJcFVWUnRrX2tIUnBKZ3pTS3ZwS2ZycktPNjZJdGhhLV83Mnc0WDZJOXVSeDR3QjNxbGlB?oc=5","date":"2018-10-24","type":"trial","source":"BioSpace","summary":"Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease - BioSpace","headline":"Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}